COR · Cencora Inc
Price
Snapshot
50 fields · last close| Market Cap | $65.06B |
| P/E | 24.79 |
| Float | 186.3M |
| Beta | 0.58 |
| Volatility | 14.6% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 81.2 |
| Price | 338.89 |
| Change | −0.60% |
| Prev Close | 340.92 |
| Open | 343.31 |
| Day Low | 339.01 |
| Day High | 343.31 |
| Avg Vol | 1 |
| Avg $ Vol | $393.3M |
| 52W High | 377.54 |
| 52W Low | 244.82 |
| 52W Pos | 70.9% |
| From High | −10.24% |
| From Low | +38.42% |
| Max DD 1Y | −32.56% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +6.60% |
| SMA 50 | +5.82% |
| SMA 200 | +6.79% |
| RSI (14) | 70.0 |
| Vol 30D | 23.3% |
| Vol 90D | 25.9% |
| 1Y Range | 245–378 |
| Daily bars | 537 |
| Perf Week | +5.27% |
| Perf Month | +10.18% |
| Perf Quarter | +12.15% |
| Perf Half Y | +5.54% |
| Perf Year | +6.74% |
| Perf YTD | +0.01% |
| Prev Day | −0.60% |
| Clavix | B+ |
| Debt / Eq | 5.08 |
| Curr Ratio | 0.90 |
| Int Cover | 6.4× |
| FCF Margin | 1.0% |
| Rev Growth | +9.3% |
| Profit | Profitable |
| Leverage | Very High |
| Sector rank | 11 / 49 |
What COR does
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.
The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics.
Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry.
The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023.
Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Clavix risk grade
regraded every trading dayCOR grades B+, 81.2 of 100. Steadiest on Macro Resilience (67), most exposed on Price Stability (66, steady). 3 of the 4 weighted dimensions sit above the Health Care median. Ranks 11 of 49 in Health Care by Clavix score.
How rough the ride is
| COR | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.58 | 0.84 |
| Volatilityannualized | 14.6% | 20.9% |
| Max drawdown, past yearworst peak-to-trough fall | −32.6% | — |
| Typical daily movemedian absolute daily change | 1.00% | — |
| Days beyond ±3%of the last 252 sessions | 13 (5%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| COR | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.58 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| COR | |
|---|---|
| 1 week | +5.3% |
| 1 month | +10.2% |
| Year to date | +0.0% |
| 1 year | +6.7% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| COR | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 5 Aug |
| Average score0 most bearish, 100 most bullish | 69 |
| Bullish · bearisharticles above 60 · below 40 | 25 · 0 |
| Directionarticles whose tone is improving vs worsening | 25 ↑ 0 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| COR | |
|---|---|
| Revenue growthyear over year | +9.3% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openAn analyst commentary argues Cencora (COR) may benefit more than Hims & Hers from AI-driven increases in prescription volumes as regulatory pilots expand automated prescribing. It cites COR's 17% year-over-year growth in adjusted operating income against 4.9% sales growth, a forward price-to-earnings ratio of 17.7x (about 25% below sector median), and sets a $365-$366 price target implying 12.5% upside.
An outside analyst reaffirmed a buy rating on Cencora, citing its investment-grade credit rating, positive operating cash flow, safe dividend, and improved operating margin as reasons the stock remains attractive despite recent underperformance.
Cencora said its board elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Sanchez is the Executive Chair of Ryder System, where he previously served as Chair and CEO until retiring in March 2026, after spending about two decades at the company.
Cencora announced it has elected Robert E. Sanchez, the Executive Chair of Ryder System, to its Board of Directors as a new independent director, effective October 1, 2026. Sanchez previously served as Chair and CEO of Ryder until his retirement in March 2026, and had been with the company for about two decades before being named CEO in 2013.
Cencora's board elected Robert E. Sanchez, the Executive Chair of Ryder System and its former CEO until March 2026, as a new independent director effective October 1, 2026.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| BSX | Boston Scientific Corp | B | $64.33B | 17.51 | 0.59 | Compare |
| CAH | Cardinal Health Inc | A- | $58.83B | 34.32 | 0.54 | Compare |
| CI | Cigna Group | A- | $79.88B | 12.45 | 0.25 | Compare |
| BDX | Becton Dickinson and Co | A- | $52.23B | 55.45 | 0.24 | Compare |
| VEEV | Veeva Systems Inc | B- | $50.25B | 49.52 | 0.88 | Compare |
| EW | Edwards Lifesciences Corp | A- | $49.92B | 49.67 | 0.84 | Compare |
| HUM | Humana Inc | B | $49.61B | 38.79 | 0.67 | Compare |
| MDLN | Medline Inc | B | $47.28B | 68.22 | 0.95 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.